-
US says Novartis updates warning on Exjade drug
Dec 14, 07 FDA warningsNovartis AG updated a warning about deaths and other health risks reported in patients treated with a drug to remove excess iron following blood transfusions, U.S. health officials said on Thursday.
The drug label was revised to include post-marketing reports of liver failure, some resulting in deaths, in patients treated with Exjade, the Food and Drug Administration said.
“Most of these events occurred in patients greater than 55 years of age,” the agency said.
WASHINGTON (Reuters)
Also in this section:
Subscribe to the "News" RSS Feed 
TOP ۞
